Imagine new medicines that precisely target and fight cancerous tumors inside a patient’s body, while resulting in fewer side effects. These promising new therapies are called antibody drug conjugates, or ADCs. Pfizer is one of the biopharmaceutical companies at the forefront of research around ADCs:
“Antibody drug conjugates, you can think of them as smart bombs basically. Precision weapons against cancer.” Robert T. Abraham, Ph.D., Senior Vice-President and Group Head, Oncology Research & Development. Mentor, Pfizer Worldwide Research and Development Postdoctoral Program
Dr. Abraham is leading a team working to unlock the promise of ADCs. This innovative therapy represents a continuing shift in the cancer treatment landscape toward personalized medicines that more accurately attacking specific targets. Because improved targeting leaves more healthy cells unharmed, they have the potential to cause fewer side effects than traditional chemotherapy – and ultimately allow patients to lead more productive and fulfilling lives.
ADCs are one of many forms of personalized medicine research underway by U.S. biopharmaceutical companies. In personalized medicine, doctors look at genetic factors to recommend individualized therapies, connecting patients to treatments that work best for them.
Learn more about this bold advancement by watching the video below.